Latest Financial Updates

Read latest financial news update from our blog

Fortrea Reports First Quarter 2025 Results | FTRE Stock News
Fortrea Reports First Quarter 2025 Results | FTRE Stock News

Fortrea (FTRE, Financial) reports a Q1 2025 revenue decline to $651.3 million, down from $...

Admin | Finance | 1 day ago

The Trade Desk Rockets 21% -- But Is Its Sky-High Valuation About to Crash?
The Trade Desk Rockets 21% -- But Is Its Sky-High Valuation About to Crash?

The Trade Desk (TTD, Financial) just delivered a knockout quarter, sending its stock up ne...

Admin | Finance | 1 day ago

Barings BDC (BBDC) Sees Price Target Cut by Wells Fargo Analyst | BBDC Stock News
Barings BDC (BBDC) Sees Price Target Cut by Wells Fargo Analyst | BBDC Stock News

Wells Fargo's analyst, Finian O’Shea, has revised the price target for Barings BDC (BBDC,...

Admin | Finance | 1 day ago

Prospect Capital (PSEC) Target Price Reduced by Analyst | PSEC Stock News
Prospect Capital (PSEC) Target Price Reduced by Analyst | PSEC Stock News

An analyst at Wells Fargo, Finian O’Shea, has adjusted the price target for Prospect Capit...

Admin | Finance | 1 day ago

Canaan Inc. to Report First Quarter 2025 Financial Results on May 20, 2025 | CAN Stock News
Canaan Inc. to Report First Quarter 2025 Financial Results on May 20, 2025 | CAN Stock News

Canaan Inc. (CAN, Financial) to release Q1 2025 financial results on May 20, 2025. Earnin...

Admin | Finance | 1 day ago

Retail investors start subscription to UCIC 2.4M shares on TASI today
Retail investors start subscription to UCIC 2.4M shares on TASI today

Retail investors will start today, May 12, subscription to 2.4 million shares of United Ca...

Admin | Finance | 1 day ago

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics | LQDA Stock News
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics | LQDA Stock News

Liquidia Corporation (LQDA, Financial) faces new patent litigation from United Therapeutic...

Admin | Finance | 1 day ago

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4R? Antibody, in Patients with Mild-to-Moderate Asthma | APGE Stock News
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4R? Antibody, in Patients with Mild-to-Moderate Asthma | APGE Stock News

APG808 achieved a 53% maximal decrease in FeNO biomarker, with a sustained 50% decrease at...

Admin | Finance | 1 day ago

Join Our Newsletter

join our newsletter to receive update from us